ReviewZeitschrift fur Gerontologie und Geriatrie2022
[Coronavirus disease 2019 and frailty].
Review in Zeitschrift fur Gerontologie und Geriatrie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Frailty after COVID-19: The wave after?Aging medicine (Milton (N.S.W)) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The course of coronavirus disease 2019 (COVID-19) varies from individual to individual. People of advanced age with comorbidities have been identified as having a higher risk for severe disease or to die from COVID-19. Frailty is an essential risk factor in this respect. Approximately one fifth of the middle European population are older than 65 years, and of these 10-15% can be categorized as frail. The pandemic brings the healthcare systems in many countries to their limits. Deciding which patients should be transferred to intensive care units (ICU) raises ethical discussions. In some countries the Rockwood Clinical Frailty Scale (CFS) is used to support this decision. Patients over 80 years of age suffering from COVID-19 show a 3.6-fold increase in the risk of mortality compared to the group aged 18-49 years. The risk of frail (CFS scores 6-9) patients is three times higher than for robust patients (CFS scores 1-3). A CFS score cut-off ≥ 6 clearly correlates with mortality of COVID-19 patients older than 65 years. Additionally, mid-term and long-term survival is determined by the degree of frailty at the time before COVID-19 rather than by the severity of the disease. Patients over 60 years are particularly at risk to develop a rapid loss of muscle mass during moderate or severe COVID-19. Patients being treated on ICUs lose 20-30% of their thigh extensor muscle mass within 10 days. The extent of sarcopenia associated with COVID-19 is decisive in determining the course of the disease and makes individually tailored rehabilitation programs necessary. Up to 50% of hospitalized patients need further rehabilitation after discharge. Aerobic training of low intensity combined with resistance training as well as a sufficient supply of calories and proteins in the diet are essential in this respect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.